RESUMO
There is a lack of evidence evaluating cryoprecipitate transfusion in severe postpartum haemorrhage. We performed a pilot cluster-randomised controlled trial to evaluate the feasibility of a trial on early cryoprecipitate delivery in severe postpartum haemorrhage. Pregnant women (>24 weeks gestation), actively bleeding within 24 h of delivery and who required at least one unit of red blood cells were eligible. Women declining transfusion in advance or with inherited clotting deficiencies were not eligible. Four UK hospitals were randomly allocated to deliver either the intervention (administration of two pools of cryoprecipitate within 90 min of first red blood cell unit requested plus standard care), or the control group treatment (standard care, where cryoprecipitate is administered later or not at all). The primary outcome was the proportion of women who received early cryoprecipitate (intervention) vs. standard care (control). Secondary outcomes included consent rates, acceptability of the intervention, safety outcomes and preliminary clinical outcome data to inform a definitive trial. Between March 2019 and January 2020, 199 participants were recruited; 19 refused consent, leaving 180 for analysis (110 in the intervention and 70 in the control group). Adherence to assigned treatment was 32% (95%CI 23-41%) in the intervention group vs. 81% (95%CI 70-90%) in the control group. The proportion of women receiving cryoprecipitate at any time-point was higher in the intervention (60%) vs. control (31%) groups; the former had fewer red blood cell transfusions at 24 h (mean difference -0.6 units, 95%CI -1.2 to 0); overall surgical procedures (odds ratio 0.6, 95%CI 0.3-1.1); and intensive care admissions (odds ratio 0.4, 95%CI 0.1-1.1). There was no increase in serious adverse or thrombotic events in the intervention group. Staff interviews showed that lack of awareness and uncertainty about study responsibilities contributed to lower adherence in the intervention group. We conclude that a full-scale trial may be feasible, provided that protocol revisions are put in place to establish clear lines of communication for ordering early cryoprecipitate in order to improve adherence. Preliminary clinical outcomes associated with cryoprecipitate administration are encouraging and merit further investigation.
Assuntos
Transfusão de Sangue/métodos , Fator VIII/administração & dosagem , Fibrinogênio/administração & dosagem , Gravidade do Paciente , Hemorragia Pós-Parto/diagnóstico , Hemorragia Pós-Parto/terapia , Adulto , Análise por Conglomerados , Feminino , Humanos , Projetos Piloto , GravidezRESUMO
Microscopic insight into interactions is a key for understanding the properties of heterogenous interfaces. We analyze local attraction in noncovalently bonded Xe-Cs^{+} aggregates and monolayers on Cu(111) as well as repulsion upon electron transfer. Using two-photon photoemission spectroscopy, scanning tunneling microscopy, and coupled cluster calculations combined with an image-charge model, we explain the intricate impact Xe has on Cs^{+}/Cu(111). We find that attraction between Cs^{+} and Xe counterbalances the screened Coulomb repulsion between Cs^{+} ions on Cu(111). Furthermore, we observe that the Cs 6s electron is repelled from Cu(111) due to xenon's electron density. Together, this yields a dual, i.e., attractive or repulsive, response of Xe depending on the positive or negative charge of the respective counterparticle, which emphasizes the importance of the Coulomb interaction in these systems.
RESUMO
The aim of this review was to understand the landscape of serum ferritin in diagnosing iron deficiency in the aetiology of anaemia in pregnancy. Iron deficiency in pregnancy is a major public health problem leading to the development of anaemia. Reducing the global prevalence of anaemia in women of reproductive age is a 2025 global nutrition target. Bone marrow aspiration is the gold standard test for iron deficiency but requires an invasive procedure; therefore, serum ferritin is the most clinically useful test. We undertook a systematic search of electronic databases and trial registers from inception to January 2016. Studies of iron or micronutrient supplementation in pregnancy with pre-defined serum ferritin thresholds were included. Two independent reviewers selected studies, extracted data and assessed quality. There were 76 relevant studies mainly of observational study design (57%). The most commonly used thresholds of serum ferritin for the diagnosis of iron deficiency were <12 and <15 ng mL-1 (68%). Most primary studies provided no justification for the choice of serum ferritin threshold used, but 25 studies (33%) used thresholds defined by expert consensus in a guideline development process. There were five studies (7%) using a serum ferritin threshold defining iron deficiency derived from primary studies of bone marrow aspiration. Unified international thresholds of iron deficiency for women throughout pregnancy are required for accurate assessments of the global disease burden and for evaluating effectiveness of interventions addressing this problem.
Assuntos
Anemia Ferropriva , Ferritinas/sangue , Ferro , Complicações Hematológicas na Gravidez , Anemia Ferropriva/sangue , Anemia Ferropriva/diagnóstico , Feminino , Humanos , Ferro/sangue , Deficiências de Ferro , Gravidez , Complicações Hematológicas na Gravidez/sangue , Complicações Hematológicas na Gravidez/diagnósticoRESUMO
BACKGROUND: The prevalence of anaemia in pregnancy in Europe is 25% and that resulting from iron deficiency is estimated at 40%. The maternal and fetal morbidity of non-anaemic iron deficiency (NAID) in pregnancy is likely to be significant. OBJECTIVES: To determine the views and opinions of health service users and clinicians concerning NAID in pregnancy in order to inform future research. METHODS: Two semi-structured focus groups were carried out to determine health service users' views on anaemia and NAID in pregnancy. A questionnaire was administered to obstetricians, haematologists, midwives and anaesthetists to elucidate their views on NAID in pregnancy. RESULTS: The study indicated that health service users and clinicians were interested in implementing testing for NAID in pregnancy with serum ferritin, if proven to be effective at reducing the effects of anaemia and improving maternal and neonatal outcomes. Clinicians had reservations in the use of intravenous iron supplementation for NAID in pregnancy. CONCLUSION: NAID is now accepted as a target condition for research by health service users and clinicians. The focus of future research should be on screening for NAID and its treatment.
Assuntos
Ferritinas/sangue , Deficiências de Ferro , Médicos , Complicações Hematológicas na Gravidez/epidemiologia , Complicações Hematológicas na Gravidez/terapia , Inquéritos e Questionários , Adulto , Atenção à Saúde , Feminino , Humanos , Ferro/sangue , Gravidez , Complicações Hematológicas na Gravidez/sangueAssuntos
Emergências , Pesquisa Qualitativa , Estudos de Coortes , Feminino , Humanos , Consentimento Livre e Esclarecido , GravidezRESUMO
The aromatase inhibitor anastrazole proved effective in the treatment of endometrial hyperplasia and postmenopausal bleeding in an obese 65-year-old woman with high operative risk. During anastrazole administration for 12 months, the endometrial thickness decreased from 9.8 mm to 2.4 mm and the control endometrial histology showed an atrophic endometrium. Uterine bleeding did not occur in the post-treatment, 3-year follow-up period. The endometrial thicknesses measured yearly by ultrasonography were 2.9, 3.5 and 3.3 mm. The plasma estradiol levels increased from < 73 pmol/l post-treatment to 112, 98 and 103 pmol/l. This case demonstrates that long-term aromatase inhibitor treatment can result in a refractory status of the endometrium and the estradiol produced in the adipose tissue does not exert a proliferative effect.
Assuntos
Hiperplasia Endometrial , Endométrio/patologia , Menopausa , Nitrilas , Triazóis , Administração Oral , Idoso , Anastrozol , Inibidores da Aromatase/administração & dosagem , Atrofia/induzido quimicamente , Hiperplasia Endometrial/tratamento farmacológico , Hiperplasia Endometrial/etiologia , Hiperplasia Endometrial/patologia , Hiperplasia Endometrial/fisiopatologia , Endométrio/fisiopatologia , Estradiol/sangue , Feminino , Humanos , Menopausa/efeitos dos fármacos , Menopausa/metabolismo , Nitrilas/administração & dosagem , Obesidade/complicações , Tempo , Resultado do Tratamento , Triazóis/administração & dosagem , Ultrassonografia/métodos , Hemorragia Uterina/etiologia , Hemorragia Uterina/patologia , Hemorragia Uterina/fisiopatologiaRESUMO
Sera from three fertile men and four infertile men without sperm antibodies, 17 infertile men with sperm antibodies in serum and seminal plasma (S.P.), and 25 infertile men with sperm antibodies in S.P. were tested by Western Blot analysis against sperm membrane extracts and S.P. from fertile nonautoimmune men and infertile autoimmune men. Sera from fertile men reacted against common antigens with molecular weights (MW) of 28, 38, 48, 60, and 68 kD present on sperm from autoimmune and nonautoimmune men and special antigen of MW 76 kD on the sperm of fertile men. Sera from 15 of 17 (88%) autoimmune infertile men with sperm antibodies in serum and S.P. detected special antigens with MW of 58 kD (sera reactivity in 47% of these men), 43kD (in 29%), 30 kD (in 24%), 35 kD (in 18%), 52 kD (in 12%), 41 kD (in 6%), and 71 kD (in 6%) on the sperm of autoimmune men in addition to the common antigens. Sera from 15 of 25 (60%) men with sperm antibodies in their S.P. showed reactivity to special antigens with MW 52 kD (in 20%), 35 kD (in 16%), 41 kD (in 16%), 58 kD (in 8%), 70/71 kD (in 8%), 30 kD (in 8%), and 56 kD (in 4%). Sera from 18 of 42 (43%) infertile men with sperm antibodies also detected special antigens of MW 26, 46, and 76 kD present only in fertile men's sperm. Sera from only 15 of 42 (36%) autoimmune infertile men reacted against special antigens with MW 17, 20, 23, 30, 43, and 58 kD in the seminal plasma of autoimmune infertile men.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Antígenos/análise , Doenças Autoimunes/imunologia , Infertilidade Masculina/imunologia , Espermatozoides/imunologia , Humanos , Masculino , Peso MolecularRESUMO
The causes and the pathomechanism of retrograde ejaculation are reported by the authors. In their case following the failure of the conservative treatment a successful intrauterine insemination was carried out in the superovulatory monitored cycle by semen are covered from the postcoital urine and washed in Ham-F-10. After an undisturbed twin pregnancy a mature male and a female infant was born using Caesarean section. There is a greater chance for pregnancy if the sperms recovered from the postcoital urine are numerous and if their motility is good.
Assuntos
Infertilidade Masculina/etiologia , Inseminação Artificial Homóloga/métodos , Adulto , Ejaculação , Feminino , Humanos , Masculino , Gravidez , Gravidez Múltipla , GêmeosAssuntos
Bromocriptina/uso terapêutico , Hiperprolactinemia/tratamento farmacológico , Lactação/efeitos dos fármacos , Período Pós-Parto/efeitos dos fármacos , Gravidez/efeitos dos fármacos , Adulto , Feminino , Humanos , Menstruação/efeitos dos fármacos , Neoplasias Hipofisárias/tratamento farmacológico , Neoplasias Hipofisárias/fisiopatologia , Período Pós-Parto/sangue , Gravidez/sangue , Prolactina/sangue , Prolactinoma/tratamento farmacológico , Prolactinoma/fisiopatologia , DesmameAssuntos
Clomifeno/análogos & derivados , Hormônios do Corpo Lúteo/deficiência , Hormônio Foliculoestimulante/deficiência , Infertilidade Feminina/tratamento farmacológico , Anovulação/etiologia , Clomifeno/uso terapêutico , Feminino , Hormônio Foliculoestimulante/biossíntese , Humanos , Infertilidade Feminina/etiologia , Hormônio Luteinizante/deficiênciaRESUMO
To evaluate the effect of body mass on the hormonal and semen profiles of subfertile men with oligozoospemia, sperm concentration and reproductive hormone levels were compared in two body mass index (BMI) groups: underweight or normal weight patients (BMI = 25 kg/m2) vs. overweight or obese patients (BMI > 25 kg/m2). The mean BMI was 27 +/- 4.6 kg/m2. The testosterone/estradiol ratio was significantly reduced in the high BMI group as compared to the low BMI group (17 +/- 4 vs. 12 +/- 3; p < 0.05). A similar difference was found in the sperm concentration (11.2 +/- 3.16 x 10(6)/ml vs. 8.1 +/- 2.6 x 10(6)/ml). A nonsignificant difference was found in the LH/FSH ratio (1.41 +/- 0.64 vs. 1.63 +/- 0.72). We concluded that obesity and the consequent estrogen excess decrease the sperm concentration by influencing the hypothalamo-pituitary system.
Assuntos
Peso Corporal/fisiologia , Estradiol/metabolismo , Oligospermia/fisiopatologia , Testosterona/metabolismo , Adulto , Índice de Massa Corporal , Hormônio Foliculoestimulante/metabolismo , Humanos , Hormônio Luteinizante/metabolismo , Masculino , Obesidade/complicações , Oligospermia/etiologiaRESUMO
A total of 274 men (aged: 26 +/- 4.9 years) with normozoospermia were enrolled into this study. Their body mass index (BMI: kg/m2) varied between 17 and 39. According to BMI, the patients were divided into four groups: Group 1: 17-20, Group 2: 20.1-25, Group 3: 25.1-30 and Group 4: 30.1-39. Twenty-nine subjects were found in the first, 96 in the second, 91 in the third and 58 men in the fourth group. Sperm concentration was significantly lower in the obese group (29 x 10(6)/ml, p < 0.05) than in the group of BMI 17-20, 20-25 and 25-30. In advance, in the obese group, sperm count continuously decreased with aging. We conclude that obesity is associated with a lower sperm count in case of normozoospermia.
Assuntos
Peso Corporal , Contagem de Espermatozoides , Adolescente , Adulto , Envelhecimento , Índice de Massa Corporal , Criança , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/fisiopatologia , Valores de ReferênciaRESUMO
This study was conducted to determine a possible relationship between regular cell phone use and different human semen attributes. The history-taking of men in our university clinic was supplemented with questions concerning cell phone use habits, including possession, daily standby position and daily transmission times. Semen analyses were performed by conventional methods. Statistics were calculated with SPSS statistical software. A total of 371 were included in the study. The duration of possession and the daily transmission time correlated negatively with the proportion of rapid progressive motile sperm (r = -0.12 and r = -0.19, respectively), and positively with the proportion of slow progressive motile sperm (r = 0.12 and r = 0.28, respectively). The low and high transmitter groups also differed in the proportion of rapid progressive motile sperm (48.7% vs. 40.6%). The prolonged use of cell phones may have negative effects on the sperm motility characteristics.
Assuntos
Telefone Celular , Sêmen/fisiologia , Motilidade dos Espermatozoides/fisiologia , Adolescente , Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Contagem de EspermatozoidesRESUMO
Cytotoxicity and Immunobead-binding immunoglobulin G assays agreed in 81% of sera from infertile men (n = 173), 74% of sera from their wives, 75% of seminal plasma, and 82% of cervical mucous samples (p less than 0.001; chi 2 analysis of positive and negative results) when tested against sperm from the same donors. Cytotoxic and immunofluorescent IgG antibody results agreed in 79% of sera from men and women, 76% of seminal plasma, and 76% of cervical mucus (p less than 0.001; chi 2 analysis of positive and negative results). Titers or percent binding of sperm by cytotoxicity, hemagglutination, and IgG Immunobead-binding or immunofluorescence assays in serum and secretions of husbands and wives correlated (p less than 0.001). A significantly increased number of positive results was observed in cytotoxic and Immunobead-binding IgG assays when the husbands' and donors' sperm were used rather than donors' sperm alone. On the basis of this study we conclude: (1) that cytotoxicity, Immunobead-binding IgG, and immunofluorescent IgG sperm antibody assays correlate when sperm from the same source are used, (2) that women's isoimmunity to husbands' sperm is associated with their husbands' autoimmunity to sperm irrespective of the assay, and (3) that it is desirable to use sperm from the husbands and nonautoimmune fertile men in these assays.
Assuntos
Anticorpos/análise , Espermatozoides/imunologia , Adulto , Autoanticorpos/análise , Autoantígenos/imunologia , Colo do Útero/imunologia , Distribuição de Qui-Quadrado , Testes Imunológicos de Citotoxicidade , Reações Falso-Negativas , Feminino , Imunofluorescência , Testes de Hemaglutinação , Humanos , Imunoglobulina G/análise , Técnicas Imunológicas , Infertilidade Feminina/imunologia , Infertilidade Masculina/imunologia , Isoanticorpos/análise , Masculino , Muco/imunologia , Análise de Regressão , Sêmen/imunologia , Motilidade dos EspermatozoidesRESUMO
Two hundred and fifty-six women were treated with clomiphene citrate. As a consequence of treatment preovulatory FSH concentration of the serum increased. There was an improvement of the luteal function in 84.0% of the patients, and 53.9% of them became pregnant. Based on the above data the authors consider clomiphene citrate suitable for treatment of luteal dysfunction. In a number of cases clomiphene treatment proved to be effective even after failure of the gonadotropin treatment.
Assuntos
Clomifeno/uso terapêutico , Corpo Lúteo/fisiopatologia , Infertilidade Feminina/tratamento farmacológico , Adulto , Corpo Lúteo/efeitos dos fármacos , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Infertilidade Feminina/fisiopatologia , Gravidez , Progesterona/sangue , Prolactina/sangueRESUMO
Spermatozoa from 15 fertile men were washed with Ham's F10 and incubated with two commercially available sperm nutrient media for 2, 4, 6, and 24 h. Both sperm capacitation medium (Irvine Scientific Co., Santa Ana, CA) and Pro-ception (Milex Products, Inc., Chicago, IL) proved to be capable of improving sperm motion characteristics. These media may be used for incubating sperm for intrauterine insemination or for in vitro fertilization.